Press releases

Intrasense attends the 70th edition of the "Journées Francophones de Radiologie" 

29 September 2022

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, is pleased to announce its participation in the Journées Francophones de Radiologie (JFR). The exhibition will be held at the Palais des Congrès in Paris. The 2022 edition is dedicated to the continuity of care pathways and to "digital health". This international medical imaging congress will gather more than 10,000 visitors between October 7 and 10

See the press release

Intrasense signs a strategic partnership with Nurea

1 June 2022

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, and Nurea, a leading provider of decision support and diagnostic software for vascular diseases, announce the signing of a partnership that will make Nurea's artificial intelligence solution available to clinicians within the
Myrian platform, through the Intrasense AI Hub.

See the press release

Intrasense launches its AI Hub in partnership with Milvue

17 May 2022

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, announces, in partnership with the company Milvue, the first integration of a solution within its Hub dedicated to artificial intelligence. The AI Hub enables the simple and ergonomic integration of artificial intelligence algorithms and their orchestration within clinical applications to better meet the
needs of users.

See the press release

Availability of the 2021 annual financial report

20 April 2022

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software
solutions and designer of Myrian®, announces today the publication of its Annual
Financial Report for the year ended December 31, 2021. This Annual Financial
Report was approved by the Board of Directors on April 19, 2022.

See the press release

TeleDiag chooses Intrasense by signing a commercial contract for teleradiology

5 April 2022

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, and TeleDiag, a leading player in teleradiology in France entered into a partnership for the deployment of the Myrian® platform to strengthen clinical efficiency and the management of cancer patients.

See the press release

Intrasense 2021 results: record business growth

10 March 2022

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and designer of Myrian®, is today publishing audited 2021 consolidated IFRS financial statements for the Group.

See the press release

Intrasense and Forcomed sign a five-year strategic partnership agreement

1 February 2022

Intrasense and Forcomed, a leading provider of continuing medical education, have entered into a five-year partnership to enable radiologists and radiology technicians to use Myrian® during a new training module on breast imagin.

See the press release

Intrasense: ambitions and publication calendar for 2022

24 January 2022

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software
solutions and designer of Myrian®, hereby sets out its ambitions, development
plan and financial publication timetable for 2022.

See the press release

Half year report of Intrasense’s liquidity contract signed with TSAF –Tradition Securities And Futures

18 January 2022

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software
solutions and designer of Myrian®, announces the publication of its half year
liquidity contract signed with TSAF – Tradition Securities And Futures.

See the press release

New product line in oncology: a milestone passed with the signature of a partnership between Intrasense and I-SERIS

5 October 2021

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software
solutions and the medical imaging and radiology group I-SERIS, which includes
the clinics of Clémentville (Montpellier), Clermont l'Hérault and the scanner center
of the Pasteur clinic in Pézenas, announce the signing of an agreement for the
development of the new oncology solution Myra.

See the press release
Subscribe